0 results for 'Sanofi SA'
The Spinmeister: David Lam | Wachtell, Lipton, Rosen & Katz
Splitting Abbott Labs in half was an undertaking of historic proportions: The Wachtell team had to spin off and finance a brand-new $54 billion pharma giant.Merger Plagued by Patent Challenges
A year ago this month, French pharmaceuticals company Aventis SA succumbed to a $69.1 billion takeover by its smaller Gallic rival Sanofi-Synth�labo SA after Paris intervened to fend off a Swiss interloper. Investors and analysts are still debating whether that move resulted in a sensible merger or was a political faux pax. A key to that answer lies in American courts, where Sanofi-Aventis SA faces patent challenges to its three biggest-selling drugs.Federal Circuit Hands Sanofi-Aventis Win in Fight Over Generic Cancer Drug
Sanofi-Aventis SA has taken its share of licks in its long-running battle with drug makers selling generic versions of Eloxatin, a drug used to treat colon cancer. Last month, the U.S. Food and Drug Administration approved the generic drugs for sale despite an appellate ruling granting Sanofi a stay of a district court order that found the generics did not infringe Sanofi's patents. But Sanofi finally got some good news on Thursday when the Federal Circuit vacated the lower court's ruling and remanded the case.Genzyme rejects Sanofi-Aventis offer
Biotechnology company Genzyme Corp. said today it rejected Sanofi-Aventis SA's $18.5 billion buyout offer because it undervalues the company.The appellate ruling comes too late to keep generic manufacturers of the colon cancer drug Eloxatin out of the market, but the Federal Circuit found that a lower court judge interpreted Sanofi's patent incorrectly when he cleared the way for its rivals.
Bristol-Myers, Sanofi-Aventis File Injunction to Stop Sales of Generic Plavix
Bristol-Myers Squibb and Sanofi-Aventis have filed an injunction against Apotex to stop the Canadian drug maker from selling a less expensive, generic version of the blood thinner Plavix. In the filing, the two brand-name makers listed several reasons the injunction should be issued, including the likelihood they will win the pending patent case and that Apotex's launch last week is causing them irreparable harm. They also said they have begun discounting Plavix to stem the loss of the drug's market share.Company Relents on Drug News Web Site
An Internet newsletter devoted to the anti-obesity drug Acomplia can keep its Web site address now that it has settled with the drug's maker, Sanofi-Aventis SA. Medical Week News Inc. launched AcompliaReport.com last year to track the progress of the drug as it goes through clinic trials and awaits approval from the U.S. Food and Drug Administration. But Sanofi-Aventis asked an international arbitrator to force Medical Week to relinquish the site name, saying it could confuse the public.Bristol-Myers, Sanofi-Aventis File Injunction to Stop Sales of Generic Plavix
Bristol-Myers Squibb and Sanofi-Aventis have filed an injunction against Apotex to stop the Canadian drug maker from selling a less expensive, generic version of the blood thinner Plavix. In the filing, the two brand-name makers listed several reasons the injunction should be issued, including the likelihood they will win the pending patent case and that Apotex's launch last week is causing them irreparable harm. They also said they have begun discounting Plavix to stem the loss of the drug's market share.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
Strong & Hanni Solves Storage Woes--Learn How You Can, Too
Brought to you by Filevine
Download Now
Meeting the Requirements of California's SB 553: Workplace Violence Prevention
Brought to you by NAVEX Global
Download Now
The Benefits of Outsourcing Beneficial Ownership Information Filing
Brought to you by Wolters Kluwer
Download Now
The Top 10 AI Use Cases in Private Equity
Brought to you by Ontra
Download Now